Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient
January 2001
Article
| Related Files |
|---|
View PDF Version
(11157994.pdf, 0.1MB) |
We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.
Keywords
- Male
- Adult
- Humans
- Drug Therapy, Combination
- Antineoplastic Agents, Hormonal/*therapeutic use
- Neoplasm Recurrence, Local/*drug therapy
- Insulin-Like Growth Factor I/metabolism
- Adenoma/complications/*drug therapy/surgery
- Human Growth Hormone/*analogs & derivatives/blood/*therapeutic use
- Octreotide/*therapeutic use
- Acromegaly/drug therapy/*etiology
- Pituitary Neoplasms/complications/*drug therapy/surgery
- Receptors, Somatotropin/antagonists & inhibitors
Automatically Extracted Terms
- pegvisomant
- serum
- patient
- concentration
- tumor size
- treatment
- octreotide
- igf-i
- tumor
- level
- acromegaly
- serum igf-i concentrations
- increase
- therapy
- study
- serum gh concentrations
- library erasmus mc
- endocrinol
- growth
- antagonist
